Last reviewed · How we verify

NCT06679803: PA-ChatS

Feasibility of a First-Line Physical Activity Intervention After Stroke

ENROLLING BY INVITATION NA Last updated 12 February 2026
What this trial tests

NA trial testing Physical Activity Chats after Stroke (PA-ChatS) in Stroke in 25 participants. Enrolling by invitation.

Timeline
5 February 2025
Primary endpoint
30 August 2026
30 December 2026

Quick facts

Lead sponsorUniversity of Minnesota
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment25
Start date5 February 2025
Primary completion30 August 2026
Estimated completion30 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with Stroke or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to explore a new intervention that supports physical activity within the first 6 weeks after stroke. All participants will complete assessments at weeks 0 and 7. During weeks 1 through 6, participants will use a Fitbit Inspire to track their step counts and meet with an occupational therapist one time per week. They will also complete weekly surveys. Physical activity levels will be measured using surveys and a wearable activPAL monitor 6 times during the study: Weeks 1, 3, 5, 7, 12, and 24.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06679803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing